Similis Bio signed a licensing and codevelopment agreement with Blau Farmacêutica, allowing the latter to have exclusive development and marketing rights to 4 biosimilar assets in Latin America.
After JSR Life Sciences launched its business unit focused on biosimilars (Similis Bio), it announced the signing of its first codevelopment and license agreement for 4 biosimilar assets with Blau Farmacêutica, a São Paulo, Brazil–based company.
The companies said the biosimilars target indications in oncology, inflammation, and blood disorders but did not disclose what molecules they will reference. However, the biosimilars will have an addressable global market of over $42 billion, $1 billion of which is Brazil’s market. The transition will take several years.
“We launched Similis Bio as we saw the need to mitigate risk and accelerate timelines for biosimilar developers…. We are thrilled to partner with Blau as they work to launch their biosimilar business initially in North and South America. We look forward to leveraging our expertise and experience to support programs that can provide additional treatment options for some of the most debilitating diseases patients face,” said John Gabrielson, senior vice president of JSR Life Sciences and head of Similis Bio, in a statement from the companies.
Under the agreement, Similis Bio will provide Blau Farmacêutica with full processes and licensing, including cell lines, analytical data and methodologies, and upstream and downstream processes. After the tranfer is complete, Blau Farmacêutica will be responsible for the domestic development and seeking regulatory approval in Latin American markets.
According to the companies, the launch of the drugs is a big milestone for Blau Farmacêutica and Brazil, which has a local producer for developing and producing active pharmaceutical ingredients (APIs) and biosimilar medicines in line with the Brazilian policies regarding independent production of APIs.
“This initiative will give the world population greater access to advanced medicines, raising the standard of care…. We are developing products for the next decade, and we will further add new products to our partnership. This strategic and disruptive agreement reinforces Blau's position in becoming a reference in the production of biosimilars in Latin America,” said Roberto Morais, executive director in charge of mergers and acquisitions and strategic alliances at Blau Farmacêutica.
As of July 2022, Brazil has 46 approved biosimilars and 7 more under review with ANVISA (The Brazilian Health Regulatory Agency), Brazil’s regulatory agency. In 2021, Celltrion Healthcare announced that it will enter the Brazilian biosimilar market, and in April 2022, the company won a 3-year tender contract for its infliximab biosimilar (Remsima). Additionally, Bio-Thera Solutions announced that it would bring a bevacizumab candidate to Brazil in December 2020. Samsung Bioepis expressed interest in entering the breast cancer and gastrointestinal markets in Brazil in August 2020 and it launched a biosimilar referencing Enbrel (etanercept) in September 2019.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.